Danaher's Q4 2025 earnings call disclosed three consecutive quarters of sequential growth in bioprocessing equipment orders following a multi-year decline, marking a potential trough in the capital equipment cycle. Management guided equipment revenue flat for 2026 versus mid-teens declines in 2025, but the improving order trajectory suggests conservative positioning.

The order book composition has shifted toward shorter-cycle projects including line additions and brownfield expansions, with management noting that "reshoring-related greenfield investments provide incremental upside over time." Orders typically lead revenue by 6-12 months, positioning 2026 for potential upside if sequential order growth continues.

The call revealed biologics surpassed small molecules in global pharmaceutical revenue for the first time in 2025, with over two-thirds of the top 100 drugs by 2030 expected to be biologics-based. This secular shift underpins the recovery in bioprocessing equipment demand and drove high single-digit growth in consumables during Q4.

Management reported new product revenue growth of 25% year-over-year, led by major launches including the SCIEX Xenotop 8600 mass spectrometer (30x sensitivity improvement for proteomics), Cytiva's 2000L single-use bioreactor, and Beckman Coulter's DXi9000 neurodegenerative assays (100x sensitivity). The innovation cadence suggests share gains rather than passive market recovery.

On capital allocation, the CEO stated "M&A environment more constructive... bias toward M&A cultivation remains as strong as ever." The company generated $5.3 billion in free cash flow in 2025 (145% conversion, the 34th consecutive year above 100%), leaving the balance sheet positioned for acquisitions.

Additional developments include Cepheid respiratory revenue guidance of $1.8 billion for 2026 (Q4 alone was approximately $500 million), with non-respiratory menu acceleration including sexual health testing up 30% and a new FDA-cleared GI panel. China volume-based procurement headwinds are moderating, with Beckman Coulter Diagnostics posting a sixth consecutive quarter of mid-single-digit growth despite pricing pressure.

The company guided 3-6% core growth for 2026 with EPS of $8.35-8.50, expecting bioprocessing to deliver high single-digit growth led by consumables with equipment revenue flat. The sequential improvement in equipment orders over three quarters against flat revenue guidance creates potential for upward revisions if the bioprocessing capital equipment cycle has bottomed.